Samir Parekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samir Parekh has a total of 701 co-authors. Here are the top co-authors by number of shared publications:
- Sundar Jagannath
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
69 shared publications - Hearn Jay Cho
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
60 shared publications - Joshua Richter
Icahn School of Medicine at Mount Sinai, New York, USA
59 shared publications - Shambavi Richard
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
56 shared publications - Santiago Thibaud
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
55 shared publications - Adriana Rossi
Icahn School of Medicine at Mount Sinai, New York, NY
52 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 8: Assessment of Loss of Heterozygosity (LOH) in Carriers of PGVs in BRCA1 and BRCA2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 8: Assessment of Loss of Heterozygosity (LOH) in Carriers of PGVs in BRCA1 and BRCA2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 2: Overall Survival (OS) in PGV-A carriers vs non-carriers
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 2: Overall Survival (OS) in PGV-A carriers vs non-carriers
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 5: Comparative Per-gene PGV-A Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 5: Comparative Per-gene PGV-A Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table1. Staging at time of enrollment, adjuvant treatment following curative intent treatment until the end of vaccination and vaccination timing
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table1. Staging at time of enrollment, adjuvant treatment following curative intent treatment until the end of vaccination and vaccination timing
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table2 – Variant count per patient
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table2 – Variant count per patient